



27 September, 2016

ZenBio, Inc. Awarded a Phase II SBIR Grant for the Continued Development of a Human Brown Adipocyte Cell Model System

RESEARCH TRIANGLE PARK, NC - ZenBio, Inc. announced that it has been awarded a Phase II SBIR grant to continue commercial development of a primary human brown adipocyte model system. The award from the National Institutes of Health will fund the second phase of development of novel human brown fat screening tools which are currently unavailable to researchers and provide a high throughput drug discovery platform to identify and validate drug targets for anti-obesity therapeutics. Obesity has reached epidemic proportions globally over the past decades causing a surge in associated comorbidities such as type II diabetes. Research targeting obesity is now a priority. In rodents, stimulation of brown adipose tissue activity and/or the browning of white adipose results in elevated energy expenditure and reduced adiposity. However, the therapeutic relevance to humans remains undefined due to the lack of a well-established human brown adipocyte system. ZenBio's human brown adipocyte program is a response to this clear and urgent need from the biopharmaceutical community for well characterized and validated human brown adipocyte platforms for biomarker validation and screening purposes. ZenBio is a global provider of human primary adipocytes and the first to commercialize a human primary white adipocyte system and is therefore uniquely positioned to generate and provide these cells. Once available, the brown adipocyte system can be used to identify novel human biomarkers and validate existing drug targets for the development of anti-obesity therapeutics. The addition of the human brown adipocyte system will significantly expand ZenBio's existing cell-based systems and screening platforms focused on metabolic diseases and related disorders.

About ZenBio, Inc.

Founded in 1995, ZenBio, Inc. (ZB) is the industry leader in robust cell-based solutions to accelerate the discovery and development of therapies to better the human condition. The ZB mission is to provide the highest quality cells, reagents and contract services to the global biomedical research, pharmaceutical and biotechnology communities within the study of human metabolic disease.

ZB pioneered tissue engineering with adult adipose-derived stem cells and is currently expanding its product offering to address a variety of developmental and onset metabolic diseases such as obesity.

ZenBio is a privately held biotechnology company, located in Research Triangle Park and has extensive worldwide distribution through a network of technically experienced partners. For more information about ZenBio, Inc., go to www.zen-bio.com

For more information, contact:

Will Plentl, Chief Operating Officer

ZenBio, Inc.

Tel. (919)-547-0692; or 1-866-ADIPOSE



Email: will@zenbio.com

www.zenbio.com

####